Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Determinants of response to CDK4/6 inhibitors in the real-world setting
Agnieszka K. Witkiewicz, Emily Schultz, Jianxin Wang, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 12

Showing 12 citing articles:

The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer
Vishnu Kumarasamy, Jianxin Wang, Costakis Frangou, et al.
Cancer Research (2024) Vol. 84, Iss. 7, pp. 1115-1132
Open Access | Times Cited: 14
Cancer takes many paths through G1/S
Erik S. Knudsen, Agnieszka K. Witkiewicz, Seth M. Rubin
Trends in Cell Biology (2023) Vol. 34, Iss. 8, pp. 636-645
Closed Access | Times Cited: 15
CDK4/6 inhibitors: The Devil is in the Detail
Tara Magge, Sneha Rajendran, Adam Brufsky, et al.
Current Oncology Reports (2024) Vol. 26, Iss. 6, pp. 665-678
Closed Access | Times Cited: 5
Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy
Thomas N. O’Connor, Emily Schultz, Jianxin Wang, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1749-1749
Open Access | Times Cited: 4
Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle
Vishnu Kumarasamy, Jianxin Wang, Michelle Roti, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer
Agnieszka K. Witkiewicz, Jianxin Wang, Emily Schultz, et al.
Oncogene (2025)
Closed Access
The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer
Furkan Ceylan, Safa Can Efil, Didem Şener, et al.
Expert Review of Anticancer Therapy (2025)
Closed Access
Real-World Data Analysis of CDK4/6 Inhibitor Therapy—A Patient-Centric Single Center Study
Isabell Ge, Kai Berner, Marlene Mathis, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1760-1760
Open Access | Times Cited: 2
DREAM On, DREAM Off: A Review of the Estrogen Paradox in Luminal A Breast Cancers
Judith Hugh, Lacey Haddon, John Maringa Githaka
Biomedicines (2024) Vol. 12, Iss. 6, pp. 1300-1300
Open Access | Times Cited: 2
Real-World Data with CDK4/6 Inhibitors—A Single Center Experience from Croatia
Iva Skočilić, Marin Golčić, Ana Marija Bukovica, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 9, pp. 895-895
Open Access | Times Cited: 2
Consequences of the perivascular niche remodeling for tumoricidal T-cell trafficking into metastasis of ovarian cancer
Danuta Kozbor, M. Winkler, N. Malhotra, et al.
Research Square (Research Square) (2024)
Closed Access
Monitoring the Response of Cyclin-Dependent Kinase 4/6 Inhibitors with Mean Corpuscular Volume
Bediz Kurt İnci, Pınar Kubilay Tolunay, Şura Öztekin, et al.
Current Oncology (2024) Vol. 31, Iss. 10, pp. 5722-5729
Open Access
Page 1

Scroll to top